转移性乳腺癌的靶向治疗-哪些分子检测是必要的?］

Journal fur Gynakologische Endokrinologie Pub Date : 2020-01-01 Epub Date: 2020-06-02 DOI:10.1007/s41974-020-00141-z

Marcus Schmidt

{"title":"转移性乳腺癌的靶向治疗-哪些分子检测是必要的?］","authors":"Marcus Schmidt","doi":"10.1007/s41974-020-00141-z","DOIUrl":null,"url":null,"abstract":"In recent years, targeted therapy for breast cancer has received increasingly more attention. In addition to hormone receptors and human epidermal growth factor 2 (HER2), the immunohistochemical detection of programmed cell death ligand 1 (PD-L1) in advanced triple-negative breast cancer and the detection of mutations in the breast cancer 1 (BRCA1) or BRCA2 gene in the patient's germline and mutations in the phosphatidylinositol 3 kinase (PI3K) pathway are currently relevant when making decisions regarding targeted therapy.","PeriodicalId":40002,"journal":{"name":"Journal fur Gynakologische Endokrinologie","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s41974-020-00141-z","citationCount":"0","resultStr":"{\"title\":\"[Targeted Therapy in Metastatic Breast Cancer-Which Molecular Tests Are Necessary?]\",\"authors\":\"Marcus Schmidt\",\"doi\":\"10.1007/s41974-020-00141-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In recent years, targeted therapy for breast cancer has received increasingly more attention. In addition to hormone receptors and human epidermal growth factor 2 (HER2), the immunohistochemical detection of programmed cell death ligand 1 (PD-L1) in advanced triple-negative breast cancer and the detection of mutations in the breast cancer 1 (BRCA1) or BRCA2 gene in the patient's germline and mutations in the phosphatidylinositol 3 kinase (PI3K) pathway are currently relevant when making decisions regarding targeted therapy.\",\"PeriodicalId\":40002,\"journal\":{\"name\":\"Journal fur Gynakologische Endokrinologie\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s41974-020-00141-z\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal fur Gynakologische Endokrinologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s41974-020-00141-z\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/6/2 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal fur Gynakologische Endokrinologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s41974-020-00141-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/6/2 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

近年来，乳腺癌的靶向治疗越来越受到人们的重视。除了激素受体和人表皮生长因子2 (HER2)外，在晚期三阴性乳腺癌中，程序性细胞死亡配体1 (PD-L1)的免疫组化检测、患者种系中乳腺癌1 (BRCA1)或BRCA2基因的突变检测以及磷脂酰肌醇3激酶(PI3K)途径的突变，目前在制定靶向治疗决策时都是相关的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Targeted Therapy in Metastatic Breast Cancer-Which Molecular Tests Are Necessary?]

In recent years, targeted therapy for breast cancer has received increasingly more attention. In addition to hormone receptors and human epidermal growth factor 2 (HER2), the immunohistochemical detection of programmed cell death ligand 1 (PD-L1) in advanced triple-negative breast cancer and the detection of mutations in the breast cancer 1 (BRCA1) or BRCA2 gene in the patient's germline and mutations in the phosphatidylinositol 3 kinase (PI3K) pathway are currently relevant when making decisions regarding targeted therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal fur Gynakologische Endokrinologie Medicine-Obstetrics and Gynecology

CiteScore

0.20

自引率

0.00%

发文量

期刊介绍： Das Journal für Gynäkologische Endokrinologie veröffentlicht Originalarbeiten, Übersichten, Fallberichte, Kurzberichte sowie Kommentare aus allen Bereichen, die Assistierte Reproduktion, Kontrazeption und Menopause betreffen. Experimentelle Untersuchungen sollten einen direkten klinischen Bezug aufweisen. Das Journal versteht sich als praxisorientiertes Fortbildungsmagazin und möchte Aktualität und Wissen vermitteln. Namhafte Expert*innen kommen zu Wort und beleuchten Schwerpunkte des Praxisalltags. Dadurch soll die Einbindung neuester Erkenntnisse in die tägliche Routinearbeit erleichtert werden.